Using epidemiology and archaeology to unearth new drug targets for rheumatoid arthritis therapy.
Epidemiological and archaeological evidence suggests that RA could be a consequence of enhanced immunity to Mycobacterium tuberculosis, and that by understanding this connection, new RA drug targets may be uncovered.
Department of Inflammation Pharmacology, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA. james.mobley@pfizer.com
James L
JL
Mobley
D018501:Antirheumatic Agents; D001106:Archaeology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D007113:Immunity, Innate / Q000235:genetics*; D014376:Tuberculosis / Q000235:genetics* / Q000276:immunology
D018501:Antirheumatic Agents